Iridex (IRIX) Net Cash Flow Growth (3y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | Iridex | 18.87 Mn | 14.27 Mn | 4.74 Mn | 20.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 4, 2026 | 20.40% |
| Jan 3, 2026 | 31.47% |
| Sep 27, 2025 | 18.04% |
| Jun 28, 2025 | 46.33% |
| Mar 29, 2025 | 51.69% |
| Dec 28, 2024 | -28.36% |
| Mar 30, 2024 | -28.08% |
| Sep 30, 2023 | -91.01% |
| Jul 1, 2023 | -64.48% |
| Apr 1, 2023 | -23.22% |
| Dec 31, 2022 | -86.00% |
| Oct 1, 2022 | 7.28% |
| Jul 2, 2022 | -21.77% |
| Apr 2, 2022 | 6.88% |
| Jan 1, 2022 | 94.89% |
| Apr 3, 2021 | 92.04% |
| Sep 26, 2020 | 30.18% |
| Jun 27, 2020 | -12.21% |
| Mar 28, 2020 | -150.51% |
| Dec 28, 2019 | -26.38% |
| Sep 28, 2019 | -12.20% |
| Jun 29, 2019 | -51.95% |
| Mar 30, 2019 | -114.06% |
| Dec 29, 2018 | 6.65% |
| Mar 31, 2018 | -160.73% |
| Sep 30, 2017 | -130.45% |
| Jul 1, 2017 | 38.64% |
| Apr 1, 2017 | -40.43% |
| Dec 31, 2016 | 188.33% |
| Oct 1, 2016 | -74.67% |
| Jul 2, 2016 | -10.70% |
| Apr 2, 2016 | 53.57% |
| Jan 2, 2016 | -13.62% |
| Apr 4, 2015 | 49.45% |
| Sep 27, 2014 | -43.19% |
| Jun 28, 2014 | -74.84% |
| Mar 29, 2014 | 36.64% |